Navigation Links
Kensey Nash Announces 400,000 Share Stock Repurchase Program
Date:12/10/2009

EXTON, Pa., Dec. 10 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) today announced that its board of directors has approved a stock repurchase. The new program allows the Company to repurchase up to a total of 400,000 of its issued and outstanding shares of Common Stock and has no scheduled expiration. The Company intends to finance the repurchases using its available cash.

Kensey Nash Corporation plans to repurchase its shares for cash, from time to time in the open market, through block trades or otherwise. The repurchase program does not require the Company to purchase any specific dollar value or number of shares. Any purchases under the program will depend on market conditions and may be commenced or suspended at any time or from time to time without prior notice. As of November 30, 2009, the Company had approximately 11,008,568 shares of Common Stock outstanding.

About Kensey Nash Corporation. Kensey Nash Corporation is a leader in developing, manufacturing and processing resorbable biomaterial products, incorporating its proprietary collagen and synthetic polymer technology. This expertise is used to develop and commercialize its products through strategic partners. The company has an extensive range of products, which are sold in multiple medical markets, including, the cardiology, orthopedic, sports medicine, spine, endovascular and general surgery markets. The company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.

Cautionary Note for Forward-Looking Statements. This press release as well as other Company press releases contains forward-looking statements that reflect the Company's current expectations about its prospects and opportunities. The Company has tried to identify these forward-looking statements by using words such as "expect," "anticipate," "estimate," "plan," "will," "would," "forecast," "believe," "guidance," "projection" or similar expressions, but these words are not the exclusive means for identifying such statements. The Company cautions that a number of risks, uncertainties and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, current economic conditions, foreign currency fluctuations, risks associated with the Company's continued research and development efforts with respect to the endovascular products (including the risk that those efforts will not be successful and that some of the associated milestone payments will not be received), Spectranetics' success in selling the ThromCat(TM) product, the Company's success in distributing its products into the marketplace, the Company's dependence on three major customers (St. Jude Medical, Arthrex and Orthovita) and their success in selling Kensey Nash related products in the marketplace, the impact of product recalls and other manufacturing issues, the Company's success in its research and development efforts in its cartilage repair and extracellular matrix technologies programs, Synthes' success in selling the Company's extracellular matrix products, the completion of additional clinical trials in both the U.S. and Europe to support regulatory approval of future generations of its products and competition from other technologies. For a detailed discussion of factors that could affect the Company's future operating results, please see the Company's SEC filings, including the disclosure under "Risk Factors" in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

SOURCE Kensey Nash Corporation


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference
2. Kensey Nash Announces $25 Million Stock Repurchase Program
3. Kensey Nash Reports Acceleration of Stock Awards Triggered by Shareholder Acquisition of Greater Than 20% of Outstanding Shares
4. Kensey Nash Reports First Quarter Fiscal Year 2008 Results
5. Kensey Nash Announces Exclusive License of Optical Guidance Patent to Enhance Chronic Total Occlusion Platform
6. Kensey Nash to Present at the 19th Annual Piper Jaffray Health Care Conference
7. Kensey Nash Corporation Announces Its Second Quarter 2008 Earnings Release Date and Teleconference
8. Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million
9. Kensey Nash to Participate in the Sidoti Twelfth Annual New York Emerging Growth Institutional Investor Forum Conference
10. Kensey Nash Reports Third Quarter Record Revenue and Sales
11. Kensey Nash to Present at the Bank of America 2008 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , is ... & Beverage and Dietary Supplement market segments across the western ... geographies east of the Rocky Mountains since 2012. Consistent performance in business ...
(Date:2/8/2016)... ... ... The Valentine’s Season is famous for gift giving with flowers, chocolates and other tokens of ... This year, for more than 5.6 million Americans suffering with Alzheimer’s, those store bought gifts ... them of the lives they’ve led and the people they’ve touched. , That’s ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling ... handle, you are not alone. According to the Center for Disease Control and Prevention ... type 2 diabetes and certain types of cancer, some of the leading causes of ...
(Date:2/8/2016)... ... 2016 , ... The Bell Agency, a full service insurance ... their ongoing community enrichment program. The current campaign fundraises for Angels & Doves, ... being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves was founded in ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted February ... (ISE®) West Awards. , Awards include the Information Security Executive® of ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Mast Therapeutics, Inc. (NYSE MKT: MSTX), a biopharmaceutical ... heart failure, today announced that it intends to offer shares ... an underwritten public offering.  The offering is subject to market ... to whether or when the offering may be completed, or ...   --> --> Roth ...
(Date:2/9/2016)... 9, 2016 Hearing protection devices refer to ... transmitted to the inner ear. Hearing protection devices include ... devices are recommended for users exposed to noise levels ... to HPD that are inserted in the ear canal ... to provide more natural sound perception with the help ...
(Date:2/9/2016)... This TforG report includes the Surgical Procedures Database with ... in South Korea . To add ... written and numerical analysis on the current trends, size, ... latest reforms of the local Healthcare system are clearly ... The report helps businesses gain a unique insight into ...
Breaking Medicine Technology: